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Background: In Benin, very few studies have been done on the genetics of Plasmodium falciparum and the resistance
markers of anti-malarial drugs, while malaria treatment policy changed in 2004. Chloroquine (CQ) and sulphadoxine
pyrimethamine (SP) have been removed and replaced by artemisinin-combination therapy (ACT). The objective of this
study was to determine the genetic diversity of P. falciparum and the prevalence of P. falciparum molecular markers that
are associated with resistance to CQ and SP in northern Benin seven years after the new policy was instituted.
Methods: The study was conducted in northern Benin, a region characterized by a seasonal malaria transmission.
Blood samples were collected in 2012 from children presenting with asymptomatic P. falciparum infections. Samples
collected in filter paper were genotyped by primary and nested PCR in block 2 of msp-1 and block 3 of msp-2 to
analyse the diversity of P. falciparum. The prevalence of critical point mutations in the genes of Pfcrt (codon 76), Pfmdr1
(codon 86), Pfdhfr (codons, 51, 59 and 108) and Pfdhps (codons 437, 540) was examined in parasite isolates by
mutation-specific restriction enzyme digestion.
Results: Genotyping of 195 isolates from asymptomatic children showed 34 msp-1 and 38 msp-2 genotypes. The
multiplicity of infection was 4.51 ± 0.35 for msp-1 and 4.84 ± 0.30 for msp-2. Only the codon 51 of Pfdhfr and codon 437
of Pfdhps showed a high mutation rate: I51: 64.4% (57.3; 71.2); G437: 47.4% (40.2; 54.7), respectively. The prevalence of
Pfdhfr triple mutant IRN (I51, R59 and N108) was 1.5% (0.3; 3.9), and Pfdhfr/Pfdhps quadruple mutant IRNG (PfdhfrI51,
R59, N108, and PfdhpsG437): 0. 5% (0; 2.5). No mutation was found with codon 540 of Pfdhps. Analysis of mutation
according to age (younger or older than ten years) showed similar frequencies in each category without significant
difference between the two groups.
Conclusions: This study showed a high diversity of P. falciparum in northern Benin with a very low prevalence of
resistance markers to CQ and SP that dramatically contrasted with the pattern observed in southern Benin. No
influence of age on genetic diversity of P. falciparum and on distribution of the mutations was observed.
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Malaria is one of the killer diseases in the world and par-
ticularly in sub-Saharan Africa where 90% of deaths due
to malaria are recorded [1]. In Benin, Plasmodium
falciparum infections are among the leading causes of
disease and are also 36% of cause of death among chil-
dren under five years (unpublished data from Ministry
of Health). Despite intensification of control methods
against malaria, multiple factors, including insecticide
resistance in anopheline vectors and the emergence and
rapid spread of drug-resistant strains, remain of major
concern in efforts to control and prevent malaria. In this
context, adequate vaccine development is a big challenge
in malaria control. However, this approach is compli-
cated by genetic diversity of P. falciparum as it influ-
ences the acquisition of protective immunity to malaria.
Asexual blood stage antigens, such as merozoite surface
protein-1 (msp-1) and merozoite surface protein-2 (msp-2)
are considered prime candidates for the development of
malaria vaccine and are also suitable markers for the iden-
tification of genetically distinct P. falciparum parasite sub-
populations [2]. These two genes are also the basis for
determining the multiplicity of infection (MOI) in infected
individuals, which is a good indicator of acquired immun-
ity or premunition of populations living in endemic areas,
and is also correlated to transmission intensity [3,4].
Following the change of malaria policy treatment in
Benin in 2004 with the replacement of chloroquine (CQ)
and sulphadoxine pyrimethamine (SP), the first- and
second-line treatment, by artemisinin combination ther-
apy (ACT) for the treatment of uncomplicated malaria,
drug pressure with these molecules has since been
reduced. Unlike in Malawi [5,6], a study performed in
southern Benin [7] revealed high rates of resistant ge-
notypes in genes Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps.
Although SP is still used in intermittent preventive treat-
ment in pregnancy (IPTp) as recommended by WHO, re-
cent observation of such high rates of resistant parasite
mutants suggested that despite the official withdrawal of
CQ and SP from the treatment of uncomplicated malaria,
these drugs were still used in Benin.
Parakou is a semi-urban city situated in the north of
the Republic of Benin and has been well characterized as
a highly endemic area with seasonal malaria transmis-
sion. However, there is no information on the genetic di-
versity of P. falciparum populations regarding resistance
markers in this area. The present study was conducted
in this locality to determine: (i) the genetic diversity of
P. falciparum based on the msp-1 and msp-2 poly-
morphism; and, (ii) the prevalence of P. falciparum mo-
lecular markers that are associated with resistance to
CQ and SP by analysing the point mutations in Pfcrt,
Pfmdr1, Pfdhfr and Pfdhps gene using samples from
asymptomatic children in northern Benin.Methods
Study sites and population
The study was conducted in the city of Parakou, a muni-
cipality in the north of Benin. It is the largest semi-
urban city in northern Benin with 188,853 inhabitants.
In the north, transmission occurrs from June to October
during the rainy season and is spread by Anopheles
gambiae s.s. (85%) and Anopheles arabiensis (15%) [8].
Children aged two to 15 years, asymptomatic and per-
manent residents of the study area, were enrolled from
May to September 2012 from nursery and primary
schools. The recruitment of these children has been de-
scribed elsewhere [7]. Inclusion criteria were: i) axillary
temperature < 37.5°C; ii) absence of fever in the previous
two weeks and at least one week after enrolment; and,
iii) positive thick smear regardless of parasite density.
Collection and handling of blood samples
Thick and thin blood smears were prepared from venous
blood, stained with 10% Giemsa for rapid diagnosis and
were examined against 500 leucocytes. Parasite densities
were recorded as the number of parasites/μl of blood as-
suming an average leucocyte count of 8,000/μl of blood.
For samples containing parasites, four separate drops of
blood were spotted and stored on to Whatman 3 filter
paper for further DNA extraction. All slides were read in
the health centre’s laboratory with external quality con-
trol of 10% of the negatives slides and all positives in the
Reference Laboratory of Parasitology of the Centre
National Hospitalier Universitaire of Cotonou. Suspected
malaria patients, following microscopy results, were
treated according to malaria treatment policy based on
ACT: artemether-lumefantrine. Parasite DNA was ex-
tracted from filter papers using the Chelex100 resin
methods [9] and stored at −20°C until use.
Molecular genotyping of the polymorphic genes
msp-1 and msp-2
Specific primer pairs were used to amplify block 2 of msp-
1 and block 3 of msp-2 [10,11]. The two genes were ampli-
fied by primary and nested PCR, each amplification with
conserved or family-specific primer pairs being done sep-
arately, as described previously [12]. Analysis of the 3D7
and FC27 allelic families of msp-2 and the K1, MAD20
and RO33 allelic families of msp-1 were sequentially per-
formed in accordance with the genotyping protocol of
Snounou et al. [12]. Allelic-specific positive controls and
DNA-free negative controls were included in each set of
reaction. Gel photographs were re-scored by visual com-
parison of DNA fragments and for individual samples,
alleles were identified according to band size and the cor-
responding allele-specific primers used. The size of the
PCR products was estimated using a 100 bp DNA ladder
marker (Boehringer Mannheim, Marker VI).
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genes and detection of Single nucleotide polymorphisms
(SNPs)
Parasite DNA was amplified with outer and nested specific
primers targeting the Pfcrt, Pfmdr1, Pfdhfr and Pfdhps
genes, as described [13-15]. The Single nucleotide poly-
morphisms in the various gene targets were detected using
the Restriction Fragment Length Polymorphism (RFLP)
technique previously reported by Ogouyemi Hounto et al.
[7]. The molecular analyses were performed in the
Molecular Biology Laboratory of the Centre de Lutte inte-
grée contre le Paludisme.Table 1 Demographic and parasitological data of the
study population
Characteristics of patients Values
Mean age (year) 7.9 ± 0.4
Age range (year) 2-15
Sex ratio (M/F) 1.03 (99/96)
Microscopy P. falciparum prevalence, 214/1,642 13%
Geometric mean parasite density (p/μl) 209.6 (161.2-272.5)
Parasite density range (p/μl) 12-86,570Data analysis
The data were entered in the software R version 2.12.0
(R Foundation for Statistical Computing, Vienna,
Austria). The distribution of allelic families of msp-1
and msp-2 genes was determined by the number of PCR
products corresponding to each family within the total
number of samples. The number of patients with more
than one amplified PCR fragment within the total popu-
lation is defined as the frequency of polyclonal infec-
tions. The MOI was determined as the number of
different msp-1 and msp-2 genotypes per isolate, and the
mean MOI was calculated as the total number of
detected P. falciparum msp-1, msp-2 genotypes/total
number of infected children [16]. Each codon was char-
acterized as wild type (no mutation present), pure mu-
tant (only mutant genotypes detected). Cases of mixed
infection (wild type and mutant) were categorized as
mutant throughout the analysis. The frequency of a par-
ticular mutant was calculated as the proportion of the
specific mutant samples among the total number of
samples successfully analysed for this mutation. Simi-
larly, the frequencies of double, triple and quadruple
mutants were determined as the proportion of subjects
with two, three and four mutations among the total
numbers of samples tested for the each. To investigate
the relationship between the mutation, MOI and age,
children were segregated into two categories: children
below and above ten years of age. This grouping resulted
from recent intensification of malaria control activities
in the country, such as the widespread distribution and
use of insecticide-treated nets and large-scale indoor
spraying of residual insecticides, which are likely to delay
the age of acquisition of immunity, usually occurring at
five years in endemic areas [17]. In areas where malaria
transmission is seasonal, the acquisition of immunity
is later than in the areas with perennial transmission.
Student’s test was used to compare MOI. The Chi-
square test or Fisher’s exact test was used for proportion
comparisons. The p value <0.05 was chosen as threshold
significance for the various statistical tests.Ethical approval
This study obtained the ethical approval of the National
Ethics Committee for Health Research of Benin.
Results
Demographic and parasitological data of the study
population
During five months, 1,642 asymptomatic children were
screened, from which 214 positive samples for P. falcip-
arum were collected on filter paper. The prevalence of
asymptomatic parasitaemia detected by microscopy was
13%, P. falciparum being the only infecting Plasmodium
species found. After the withdrawal of children above
15, 195 samples were selected for molecular analysis.
Characteristics of the study population are detailed in
Table 1. Children’s ages ranged from two to 15 years
(mean age: 7.9 ± 0.4 years). The parasite density ranged
from 12 to 86,570 parasites/μl with a geometric mean
density of 209.6 (161.2-272.5).
The parasite DNA from the 195 P. falciparum isolates
were analysed for msp-1 and msp-2 genes. The efficiency
of msp-1 and msp-2 genes amplification reactions with
family-specific primers was 99% (193/195) and 99.5%
(194/195), respectively.
Regarding the analysis of the mutation, the number of
isolates depended on the success of PCR amplification
and was 195 for Pfcrt (100%), 193 (99%) for Pfmdr1, 192
(98.5%) for Pfdhps and 194 (99.5%) for Pfdhfr. Samples
that were retested to check the reproducibility of results
were consistent with those found initially.
Genetic diversity of Plasmodium falciparum
msp- 1 and msp-2 gene
A total of 72 individual msp alleles were identified (34 for
msp-1 and 38 for msp-2). The K1 family was the predom-
inant allelic type among monoclonal infections (17.1%), in
mixed infection with Mad20 (13.5%) and RO33 (11.9%).
This family was also more represented (p < 0.01) in overall
population (90.7%). Mad20 and Ro33 families were
found respectively in 67.4 and 66.8% of isolates. For
msp-2 gene, the FC27 family was more represented but
not statistically significant (p = 0.57). The distribution of
Table 2 Prevalence of molecular markers associated with
Plasmodium falciparum resistance to chloroquine and




n (%) <10 years ≥10 years P
valuen (%) n (%)
T76 (n = 195) 56 (28.7) 38 (31.1) 18 (24.7) 0.42
Y86 (n = 193) 47 (24.4) 26 (22) 21 (28) 0.44
T76Y86 (n = 193) 10 (4.6) 6 (4.4) 4 (4.8) 1.00
G437 (n = 192) 91 (47.4) 56 (47.5) 35 (47.3) 0.90
E540 (n = 192) 0 (0) 0 (0) 0 (0)
I51 (n = 194) 125 (64.4) 76 (61.8) 49 (69) 0.39
R59 (n = 194) 50 (25.8) 29 (24.2) 21 (28.4) 0.63
N108 (n = 194) 35 (18) 24 (20.2) 11 (14.7) 0.44
IRN (n = 194) 3 (1.5) 1 (0.7) 2 (2.4) 0.56
IRNG (192) 1 (0.5) 0 1 (1.2) 0.38
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shown in Additional file 1: Table S1.
The number of msp-1 and msp-2 genotypes per isolate
ranged from one to 11. MOI was 4.51 ± 0.35 for msp-1
and 4.8 ± 0.30 for msp-2. According to age, MOI was
4.8 ± 0.43 in children below ten and 4.1 ± 0.59 in older
children with msp-1 gene (p = 0.06). Regarding msp-2
gene, MOI was 4.3 ± 0.46 and 3.9 ± 0.60, respectively, in
children below ten and older children, respectively, p =
0.18. Multiple infections were found in 71.5% (138/193)
for msp-1 and 91.7% (178/194) for msp-2.
Prevalence of Pfcrt and Pfmdr1, alleles and mutations
The wild type alleles K76 and N86 of Pfcrt and Pfmdr1
gene, respectively, were present in 71.3% (139/195) and
75.6% (146/193) of samples from patients that were ana-
lysed, whereas mutant and mixed alleles were poorly
represented (Figure 1). Thus, prevalence of T76 muta-
tion was 28.7% (56/193) (22.5; 35.6), while Y86 was
found in 24.4% (47/193) (18.5; 31.0) (Table 2).
Prevalence of Pfdhps and Pfdhfr allelic forms
Pfdhps
At codon 437, the wild type allele A437 (52.6%: 101/
192) was more represented in the population than mu-
tant (G437: 24.5%: 47/192) and mixture of alleles
(A437/G437: 22.9%: 44/192), P < 0.01. However, all sam-
ples carried the wild type allele K540 of codon 540 and
no mutation E540 was found (Figure 2, Table 2). Over-
all, mutation of codon 437 (G437) was found in 47.4%
(40.2; 54.7) of the samples analysed (91/192).
Pfdhfr
Except for codon 51 in which mutated alleles were more
represented (I51: 55,7%: 108/194), the analysis of other co-
dons showed high prevalence of wild type alleles. Allele
C59 were found in 74.2% of the samples (144/194) and
S108 in 82% (159/194) (Figure 3). Thus, a high prevalence
of mutant genotypes was observed only at codon 51 (I51:
64.4% (125/194) (57.3; 71.2)) compared to other codonsFigure 1 Prevalence of Pfcrt and Pfmdr1 alleles.where the prevalence of mutants remained very low (R59:
25.8% (50/194) (19.8; 32.5), N108: 18% (35/194) (12.9;
24.2)) (p < 0.01). Combined analysis of the different Single
nucleotide polymorphisms revealed that the prevalence of
Pfdhfr triple mutant IRN (I51, R59 and N108) and Pfdhfr/
Pfdhps quadruple mutant IRNG (Pfdhfr I51, R59, N108,
and PfdhpsG437) was actually very low: IRN: 1.5% (3/194)
(0.3; 3.9), IRNG: 0.5% (1/192) (0; 2.5) (Table 2).Mutation and age
When the data were analysed by age categories, similar
frequencies of single, triple and quadruple mutant para-
site were found in children younger than ten years and
in older children (Table 2).Mutation and polyclonality
The analysis showed similar frequency of single, double,
triple and quadruple mutation in monoclonal and poly-
clonal infections regardless of the gene (msp-1 or msp-2).Figure 2 Prevalence of pfdhps alleles.
Figure 3 Prevalence of Pfdhfr alleles.
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sented in polyclonal infections of msp-1 gene (Table 3).Discussion
In the Republic of Benin, less attention had been put on
the investigation of the genetic diversity of P. falciparum
and on the molecular markers of P. falciparum resistance
to CQ and SP since the change of malaria treatment policy
in 2004. The purpose of this study was to determine the
genetic diversity of P. falciparum using the two most poly-
morphic regions of msp-1 and msp-2 genes, and the
prevalence of molecular markers of P. falciparum to CQ
and SP in malaria asymptomatic subjects in northern
Benin. This analysis intends to develop efficient strategies
for malaria control, and improve the surveillance of the
actual level of P. falciparum resistance to anti-malarial
drugs in Benin.Table 3 Mutation and polyclonality
Mutations Msp-1 (n = 193)
Monoclones Polyclones p-va
n (%) n (%) n (%
n = 55 n = 138
n (%) n (%)
T76 19 (34.5) 37 (26.8) 0.10
Y86 9 (16.4) 38 (27.5) 0.40
T76Y86 5 (9.1) 5 (3.6) 0.13
G437 14 (25.5) 77 (55.8) 0.01
I51 31 (56.4) 94 (68.1) 0.48
R59 15 (27.3) 35 (25.4) 0.44
N108 10 (18.2) 25 (18.1) 0.74
IRN 2 (3.6) 1 (0.7) 0.07
IRNG 1 (1.8) 0 0.56This study follows a previous one that was conducted in
southern Benin [7]. Allele-specific genotyping of msp-1
and msp-2 showed a high genetic diversity in the P. falcip-
arum population studied in Parakou with a MOI of 4.5
(msp-1) and 4.8 (msp-2). This figure is similar to that ob-
served in southern Bénin (unpublished data). Actually, a
minimum of 34 alleles of msp-1 were observed, in which
the K1 allelic family was predominant, consistent with the
previous study [18-21] but in contrast to Barty [22] in
India showing that RO33 family was predominant. For the
msp-2 locus, 38 alleles were found and alleles belonging to
FC27 family were mostly detected, both in mono-infection
and mixed infection with 3D7 alleles. Although this is
similar to data reported in Congo [23], it differs from pre-
vious results of Issifou et al. in south Benin [19], and
Mayengue et al. in Congo Brazzaville [24]. The difference
with the results of Issifou et al. may be due to the fact that
the study goes far back in the past. Indeed, according
Yuang et al. in Myanmar [25], the majority of alleles
showed significant temporal fluctuations through the
years. The high rate of multiple infections of P. falciparum
infections with msp-1 and msp-2 found elsewhere [16,26]
would probably be a consequence of intense malaria trans-
mission of study areas. Actually, the mean MOI was high
compared to those reported in Benin, Burkina Faso,
Congo Brazzaville [18,19,24], but consistent those from
Gabon and Senegal [20,27]. The high rate of MOI in the
present study suggests that, despite the intensification of
malaria control interventions involving reduction of mal-
aria infections, the parasite population size and transmis-
sion intensity remained high enough to allow effective
genetic recombination of the parasites and continued
maintenance of genetic diversity. The fact that MOI was
not influenced by age as shown in other countries [28,29]
suggests that the MOI is not directly related to the periodMsp-2 (n = 194)
lue Monoclones Polyclones p-value
) n (%)
n = 16 n = 178
n (%) n (%)
6 (37.5) 50 (28.1) 0.39
1 (6.3) 46 (25.8) 0.23
0 10 (5.6) 0.78
6 (37.5) 85 (47.7) 0.96
8 (50.0) 117 (65.7) 0.77
2 (12.5) 48 (27) 0.49
1 (6.3) 34 (19.1) 0.46
0 3 (1.7) 1.00
0 1 (0.6) 1.00
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reflects the exposure of subjects to malaria in endemic area.
The major finding of this study is that analysis of well-
characterized molecular markers of P. falciparum resist-
ance to CQ and SP, two anti-malarials that have long
been used in the treatment of uncomplicated malaria in
Benin, revealed contrasted low prevalence of resistant
genotypes in northern Benin as opposed to the south
[7]. A low prevalence of T76 (28.7%) mutation associ-
ated with resistance to CQ was observed in this study
compared to the study carried out in the south in 2011
where a high prevalence of this mutation was observed,
indicating a persistence of resistance to CQ seven years
after the change of malaria treatment policy. The same
goes for the quadruple mutation associated with resist-
ance to SP, which is very low in this setting compared to
data reported in southern Benin. The dramatic differ-
ence between the results could be explained by a higher
drug pressure in southern Benin. Parakou is a semi-
urban city 407 km from Cotonou in the north of the
country where self-medication and a parallel market for
counterfeit drugs are lower than in the south, where
proximity to Nigeria promotes drug traffic and pressure.
Duah et al. in Ghana [30] observed an increase of drug-
resistant genotypes in the urban setting compared to
rural areas. Some studies [31,32] have shown the selec-
tion of sensitive phenotypes of Pfcrt and Pfmdr1 gene
after stopping the use of CQ and extending the use of
the AL. Data in southern Benin where the policy change
was made at the same time does not show this reversion
and still is an extremely high prevalence of pfcrt and
Pfmdr1 mutants [7]. However, the likely effect of the
introduction of artemether-lumefantrine in the explan-
ation of this phenomenon, which may be even more
pronounced in areas where the pressure is lower like
north Benin can be taken into account.
The migration of parasites related to population move-
ments between the north and south of Benin could in-
crease the prevalence of resistant parasites. However the
inclusion of children living in Parakou for at least six
months has probably allowed the minimizing of such a
risk. This does not preclude transmission of resistant
parasites by mosquito bites on persons in transit har-
bouring resistant parasites. Certainly the magnitude of
this phenomenon is minimal and not enough to signifi-
cantly increase the proportion of resistant parasites.
As malaria treatment policy was harmonized in the
country when policy change was decided in 2004, it had
not been taken into account places where low rates of
treatment failure had been noted. Indeed, in Parakou in
2002, in vivo efficacy studies conducted according to
WHO protocol [33] reported 13.9% of treatment failure
with CQ (4.6 and 9.3% early and late treatment failures,
respectively), which was lower compared to the nationalaverage of 35.2% treatment failure (unpublished data
from NMCP of Ministry of Health). Based on the associ-
ation between treatment failure to CQ and the preva-
lence of T76 mutation [13,34], the results in this study
rather suggest the existence of a small proportion of mu-
tation T76 before the policy change. This also suggests
that the low prevalence observed in this study is unlikely
to result from the re-emergence of susceptible strains re-
lated to the reduction of drug pressure.
Regarding SP, the therapeutic failure rates observed in
2002 in Parakou were 3.3% (1.6 and 1.7% early and late
treatment failures, respectively) against the 22.8% na-
tional average. Given the relation between triple Pfdhfr
mutations, double Pfdhps mutations and clearance of
parasitaemia after SP treatment [35-37], the very low
rates of parasite with quadruple Pfdhfr Pfdhps mutant
(IRNG: 0.5%) found in this study, suggests that there
was very little parasite resistance to SP in the study area
before the withdrawal of the drug from the treatment of
uncomplicated malaria in 2004. In this study, the high
mutation rates on codon 51 quite surprising, which al-
most twice the level in the codon 108 mutation was ob-
served. There is no logical explanation for this, but in
some studies mutation rates of codon 51 and 108 ap-
peared to be substantially the same as described by
Dicko et al. [38], and the selection of mutants could be
faster with the codon 51. It is likely that the use of SP in
IPTp did not contribute to an increase in the rate of re-
sistant parasites, in agreement with studies reported in
Senegal and Mali [38,39]. The data generated in this
study suggest that these two molecules could still be
used in the treatment of malaria in Parakou, however,
the difficulty in policy management of malaria in the
country argues for a harmonized strategy.
The proportion of infections by parasites carrying spe-
cific mutations between children younger than ten years
and older children suggests that age does not influence the
distribution and carriage of resistant parasites whatever the
type of mutation, as shown elsewhere [7,40]. To investigate
whether the mutation patterns were influenced by poly-
clonality, the parasite isolates were classified as monoclonal
and polyclonal. Apart from the G437 mutation, which was
more prevalent in polyclonal infections, all other muta-
tions: single, double, triple or quadruple, were distributed
similarly in both groups regardless of the gene. These re-
sults suggest that the number of clones is not directly in-
volved in the carriage of mutant parasites. However, it
would be interesting to investigate the link between poly-
clonality and mutation in a population with high preva-
lence of mutation in order to draw better conclusions.
Conclusions
This study showed a high diversity of P. falciparum in
northern Benin irrespective of age in asymptomatic
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parasite resistance to CQ and SP, indicating that most P.
falciparum strains are still potentially sensitive to these
molecules in this part of the country. These results strongly
opposed to those in the south which shows the need to
map molecular markers of resistance in different regions of
endemic countries, taking into account the drug pressure.
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